Prominent Clinical Researchers Bring Significant Expertise in Inherited Retinal Diseases
Clinical Advisory Board Will Initially Focus on PYC's Lead Drug Candidate, VP-001 for the Treatment of Retinitis Pigmentosa Type 11, for which the Company Expects Larger Animal Data Readouts in 2H 2021 and an Investigational New Drug filing in mid-2022
PR Newswire
SAN DIEGO and PERTH, Australia, Aug. 17, 2021